113359-04-9

Basic information

• Product Name: Cefozopran
• Synonyms: CEFOZOPRAN;sce2787;1-[[(6R,7R)-7-[[2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]imidazo[1,2-b]pyridazinium Inner Salt;Firstci;SCE-1787;1-[[(6R,7R)-7-[[(2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium hydroxide inner salt;Firstcin);SCE-2787：Fastocin
• CAS NO: 113359-04-9
• Molecular Formula: C19H17N9O5S2
• Molecular Weight: 515.53
• EINECS: 1806241-263-5
• Product Categories: Cefozopran Hydrochloride and its intermediates;Antibacterial;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 113359-04-9.mol
• Article Data: 0

Chemical Properties

• Melting Point: >300°C
• Appearance: white to pale-yellow powder
• Density: 1.59 g/cm3
• CAS DataBase Reference: Cefozopran(CAS DataBase Reference)
• NIST Chemistry Reference: Cefozopran(113359-04-9)
• EPA Substance Registry System: Cefozopran(113359-04-9)

Safety Data

• Hazardous Substances Data: 113359-04-9(Hazardous Substances Data)

Usage

Chemical Properties

White To Pale-Yellow Powder

Uses

Antibacterial

Antimicrobial activity

An aminothiazole cephalosporin formulated as the hydrochloride. Activity is similar to that of ceftazidime, but it is more active against methicillin-susceptible staphylococci (MIC 1 mg/L). Representative MICs against Gram-negative species are: Esch coli 0.25 mg/L; K. pneumoniae 1 mg/L; Ps. aeruginosa 1–8 mg/L. Activity against Acinetobacter spp., Sten. maltophilia and B. fragilis group is poor. A 20-min infusion of 1.5 g achieved a plasma concentration of around 125 mg/L at the end of infusion. Almost 90% of the dose was excreted in the urine over 24 h. The mean terminal half-life was around 2 h. Adverse reactions appear to be typical of those of other group 6 cephalosporins. It is available in Japan.

InChI:InChI=1/C19H17N9O5S2.ClH/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27;/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32);1H/b24-11+;/t12-,17-;/m1./s1

Related news

Penetration into and exposure of Cefozopran (cas 113359-04-9) in pelvic retroperitoneal space exudate08/14/2019

This study aimed to examine the penetration into and exposure of cefozopran in the pelvic retroperitoneal space exudate of patients undergoing radical hysterectomy and pelvic lymphadenectomy. Cefozopran (1 g) was administered by 1-h infusion after the end of surgery, and venous blood and exudate...detailed

Original articleOn the isomerisation of Cefozopran (cas 113359-04-9) in solution08/13/2019

In this study, we first described the two configurations of cephalosporins by cefozopran, then determined their molecular structure and finally evaluated the stability and biological activity of the two configurations. Our results showed that cefozopran existed as two different configurations in...detailed

Research articleRadiolytic studies of Cefozopran (cas 113359-04-9) hydrochloride in the solid state08/12/2019

BackgroundThe radiation sterilization is one of the best methods for sterilizing vulnerable degradation drugs like cefozopran hydrochloride.detailed